ProShares Ultra NASDAQ Biotechnology
28 hedge funds and large institutions have $7.07M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 13 closing their positions.
2.49% less ownership
Funds ownership: 8.2% → 5.7% (-2.5%)
24% less funds holding
Funds holding: 37 → 28 (-9)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
30% less call options, than puts
Call options by funds: $1.99M | Put options by funds: $2.85M
56% less capital invested
Capital invested by funds: $16M → $7.07M (-$8.88M)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JF
Jump Financial
Chicago,
Illinois
|
+$510K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$322K |
| 3 |
Walleye Capital
New York
|
+$272K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$93.8K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$1.83M |
| 2 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
-$1.81M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$907K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$659K |
| 5 |
HF
HRT Financial
New York
|
-$536K |
BIB Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2022, worth a combined $7.07M — down 56% from $16M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BIB and 4 opened new positions — a net loss of 9 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Jump Financial, opening a new position worth an estimated $510K. The largest seller was Old Mission Capital, cutting an estimated $1.83M.
- 28 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2022, down from 37 in Q4 2021.
- Funds reported $7.07M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2022, down 56% quarter-over-quarter.
- 4 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2022 and 13 closed out, a net change of -9 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2022 was Jump Financial, an estimated $510K added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2022 was Old Mission Capital, an estimated $1.83M sold.
Based on aggregated 13F filings for Q1 2022.